Sangamo Therapeutics Inc (SGMO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sangamo Therapeutics Inc (SGMO) has a cash flow conversion efficiency ratio of -4.565x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.50 Million) by net assets ($6.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SGMO net asset quality index to measure how much of total assets are equity-financed.
Sangamo Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Sangamo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Sangamo Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
Sangamo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sangamo Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bellway PLC
LSE:BWY
|
-0.001x |
|
Harvard Bioscience Inc
NASDAQ:HBIO
|
-0.066x |
|
Bowen Acquisition Corp Ordinary Shares
NASDAQ:BOWN
|
0.000x |
|
Scienjoy Holding Corp
NASDAQ:SJ
|
0.008x |
|
Salee Industry Public Company Limited
BK:SALEE
|
0.023x |
|
GWR Group Ltd
AU:GWR
|
0.020x |
|
Nova Leap Health Corp
V:NLH
|
0.021x |
|
BuzzFeed Inc
NASDAQ:BZFD
|
0.073x |
Annual Cash Flow Conversion Efficiency for Sangamo Therapeutics Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Sangamo Therapeutics Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see SGMO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $22.77 Million | $-67.14 Million | -2.949x | -8.70% |
| 2023-12-31 | $82.89 Million | $-224.84 Million | -2.713x | -257.79% |
| 2022-12-31 | $294.96 Million | $-223.63 Million | -0.758x | -22.00% |
| 2021-12-31 | $375.34 Million | $-233.25 Million | -0.621x | -281.95% |
| 2020-12-31 | $497.37 Million | $169.88 Million | 0.342x | +202.35% |
| 2019-12-31 | $432.74 Million | $-144.40 Million | -0.334x | -429.20% |
| 2018-12-31 | $366.52 Million | $37.15 Million | 0.101x | +70.38% |
| 2017-12-31 | $187.90 Million | $11.18 Million | 0.059x | +112.30% |
| 2016-12-31 | $136.19 Million | $-65.88 Million | -0.484x | -176.07% |
| 2015-12-31 | $192.44 Million | $-33.72 Million | -0.175x | -538.01% |
| 2014-12-31 | $206.63 Million | $-5.67 Million | -0.027x | +82.84% |
| 2013-12-31 | $121.71 Million | $-19.48 Million | -0.160x | -28.53% |
| 2012-12-31 | $64.90 Million | $-8.08 Million | -0.125x | +61.46% |
| 2011-12-31 | $80.13 Million | $-25.89 Million | -0.323x | +24.51% |
| 2010-12-31 | $55.91 Million | $-23.93 Million | -0.428x | -400.74% |
| 2009-12-31 | $71.78 Million | $-6.14 Million | -0.085x | +72.69% |
| 2008-12-31 | $55.40 Million | $-17.34 Million | -0.313x | -40.54% |
| 2007-12-31 | $72.12 Million | $-16.07 Million | -0.223x | +25.05% |
| 2006-12-31 | $48.70 Million | $-14.48 Million | -0.297x | -176.25% |
| 2005-12-31 | $37.81 Million | $-4.07 Million | -0.108x | +65.72% |
| 2004-12-31 | $32.38 Million | $-10.16 Million | -0.314x | -88.44% |
| 2003-12-31 | $44.66 Million | $-7.44 Million | -0.167x | +6.57% |
| 2002-12-31 | $54.25 Million | $-9.67 Million | -0.178x | -140.42% |
| 2001-12-31 | $82.35 Million | $-6.11 Million | -0.074x | -102.14% |
| 2000-12-31 | $66.89 Million | $-2.45 Million | -0.037x | +87.92% |
| 1999-12-31 | $7.90 Million | $-2.40 Million | -0.304x | -- |
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a ch… Read more